Navigation Links
Dr. Ritchie Shoemaker Certifies Third Physician in His Treatment Protocol for Chronic Inflammatory Response Syndrome (CIRS)
Date:5/20/2013

Pocomoke, Maryland (PRWEB) May 20, 2013

In Early 2013, Dr. Ritchie Shoemaker, internationally recognized leader in the field of biotoxin related illnesses, announced his vision for creating a network of physicians across the country able to advance his protocol for treating Chronic Inflammatory Response Syndrome (CIRS). This week, Dr. Raj Patel became the third physician to achieve certification in the Shoemaker Protocol.

“Creating a network of Certified Physicians, able to practice the Shoemaker Protocol in other parts of the country, is enabling patients who need qualified medical help to find that help closer to home… Dr. Patel is a strong addition to the network, bringing the Protocol to the West Coast for the first time.” reported Dr. Shoemaker, who has been practicing in Maryland for decades. The Shoemaker Protocol is a step by step process of treating patients suffering from biotoxin related illnesses using differential diagnosis and proven scientific fundamentals. Dr. Shoemaker works one on one with candidates of the program to ensure a complete mastery of the practice.

Dr. Raj Patel, the third physician to become certified by Dr. Shoemaker, is a Rutgers University and Robert Wood Johnson Medical School graduate. He has specialized in treating patients with Autistic Spectrum Disorders (ASD), as well as Lyme disease, and more recently, biotoxin illness resulting from exposure to water damaged buildings. Since beginning his work with Autism in 1999, he has helped over 700 children, as well as working with other childhood developmental conditions including ADD/ADHD, OCD, and developmental delay. He is an active Member of Defeat Autism Now (DAN), and the International Lyme and Associated Diseases Society (ILADS).

According to Dr. Shoemaker, “The Shoemaker Protocol slowly brings back a life filled with meaning and fullness, vitality and insight, as the new therapies correct the immunologic disease often called mold illness.”

About Dr. Ritchie Shoemaker - Ritchie Shoemaker, MD, is an internationally recognized leader in education, patient care, and research in the field of biotoxin related illness, and has treated over 6,000 patients. Dr. Shoemaker has written numerous papers and eight books, including the widely read Surviving Mold, and Mold Warriors. After announcing his retirement from active patient care in January 2013, he has dedicated his time to developing a network of physicians certified in the Shoemaker Protocol, continuing his research in the biotoxin illness field, giving lectures and attending conferences on the subject.

Read the full story at http://www.prweb.com/releases/2013/5/prweb10743966.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Dr. Ritchie Shoemaker Proudly Announces First Graduate of Shoemaker Protocol Certification Training
2. Dr. Ritchie Shoemaker Pleased to Announce Second Physician Achieves Shoemaker Protocol Certification for Treating Chronic Inflammatory Response Syndrome
3. Novocure™ Certifies Eight Additional Clinical Centers of Excellence to Treat Most Common Brain Tumor with Tumor Treating Fields (TTFields) Therapy
4. Fidelis Companies Certifies 14 Recruiters; Certified Personnel Consultant (CPC) and Certified Temporary-Staffing Specialist (CTS) Designation from NAPS Awarded
5. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
6. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
7. WuXi PharmaTech Announces Third-Quarter 2011 Results
8. Interleukin Genetics Reports Third Quarter 2011 Financial Results
9. Spherix Announces Third Quarter Financial Results
10. Nile Therapeutics Reports 2011 Third Quarter Financial Results
11. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... Fla. , Feb. 16, 2017  MDNA ... revolutionizing the development of liquid biopsy tests based ... entered into an exclusive license agreement with its ... MDNA,s proprietary liquid biopsy test for prostate cancer, ... South Korea . This is the first ...
(Date:2/16/2017)... Mass. , Feb. 16, 2017   Biostage, ... the "Company"), a biotechnology company developing bioengineered organ implants ... esophagus, bronchus and trachea, announced today the closing on ... of 20,000,000 shares of common stock and warrants to ... proceeds of $8.0 million. The offering was priced at ...
(Date:2/16/2017)... Feb. 16, 2017  Champions Oncology, Inc. (NASDAQ: ... and sale of advanced technology solutions and products to ... announced the addition of new cohorts of PDX models ... models will expand Champions, product line in hepatocellular cancer, ... cancer, AML, and non-small cell lung cancer (including EGFR ...
(Date:2/16/2017)... and NEW YORK , Feb. ... near completion of their $7M Series B financing, adding ... of the $3.5M led by Mesa Verde Venture Partners ... These resources will be directed towards further accelerating commercial ... a comprehensive genomic profiling test and expanding the Paradigm ...
Breaking Biology Technology:
(Date:2/2/2017)... , Feb. 2, 2017   TapImmune, ... clinical-stage immuno-oncology company specializing in the development of ... the treatment of cancer and metastatic disease, announced ... and GMP manufacturing of a second clinical lot ... targeting folate receptor alpha. The manufactured vaccine product ...
(Date:2/2/2017)... Feb. 1, 2017  Central to its deep ... advances worldwide, The Japan Prize Foundation today announced ... have pushed the envelope in their respective fields ... Three scientists are being recognized with the 2017 ... not only contribute to the advancement of science ...
(Date:1/31/2017)...  Spero Therapeutics, LLC, a biopharmaceutical company founded ... bacterial infections, today announced it has acquired a ... Bono Bio Ltd (PBB) to bolster its pipeline ... of Gram-negative bacteria.   The assets acquired have been ... group company. "The acquisition of these ...
Breaking Biology News(10 mins):